AOD-9604 vs Fragment 176-191

AOD-9604 vs Fragment 176-191: Overview

AOD-9604 and fragment 176-191 are two closely related peptides derived from human growth hormone (hGH), both of which have attracted significant research interest for their potential roles in lipid metabolism and fat reduction. Although they share a common origin in the C-terminal region of hGH, these peptides differ in important structural and functional ways. Understanding the relationship between fragment 176-191 vs AOD-9604 requires examining their molecular modifications, mechanisms of action, and the body of preclinical and clinical evidence that has accumulated around each compound.

Fragment 176-191 refers to the naturally occurring C-terminal segment of human growth hormone, spanning amino acids 176 through 191. Early investigations into hGH fragments during the late 1970s and 1980s identified this region as possessing metabolic activity distinct from the full-length hormone. AOD-9604, by contrast, is a modified synthetic derivative of this fragment that incorporates a specific chemical alteration—the addition of a tyrosine residue at the C-terminus—designed to stabilise the molecule and potentially enhance its lipolytic properties. This distinction is critical when evaluating AOD 9604 vs hGH fragment, as the structural modification may influence pharmacological behaviour, receptor interactions, and downstream metabolic effects.

Both peptides have been investigated primarily in the context of obesity research and metabolic disease, though their trajectories through the research pipeline have diverged considerably. Fragment 176-191 has remained largely a research tool used in preclinical studies, while AOD-9604 advanced to clinical trials before ultimately failing to demonstrate sufficient efficacy for regulatory approval as an anti-obesity agent. More recently, AOD-9604 has been explored in osteoarthritis research, suggesting its biological activities may extend beyond lipid metabolism.

Mechanism of Action

The mechanism of action of both fragment 176-191 and AOD-9604 centres on the lipolytic properties attributed to the C-terminal region of human growth hormone. Research suggests that this region of hGH is responsible for the fat-mobilising activity of the full-length hormone, operating independently of its growth-promoting and diabetogenic effects. Early studies by Ng and Bornstein (1978) demonstrated that synthetic C-terminal fragments of hGH could modulate glucose metabolism in adipose tissue, establishing the concept that specific regions of the growth hormone molecule carry distinct metabolic functions.

Fragment 176-191 appears to stimulate lipolysis and inhibit lipogenesis in adipocyte models through mechanisms that do not involve the classical growth hormone receptor signalling pathway. Preclinical data indicates that this fragment enhances β-adrenergic-mediated lipolysis without producing the insulin resistance or hyperglycaemic effects associated with full-length growth hormone. Studies by Ng and colleagues throughout the 1980s further characterised the metabolic actions of related hGH fragments, demonstrating their ability to stimulate glucose transport in adipocytes through mechanisms involving cellular mediators distinct from insulin signalling.

AOD-9604 retains these lipolytic properties while incorporating structural modifications intended to improve metabolic stability. The tyrosine addition at the C-terminus provides a handle for potential disulfide bond formation, which may enhance the peptide’s conformational stability in biological environments. Research by Heffernan et al. (2001) in chronic treatment models in obese mice demonstrated that AOD-9604 reduced body weight gain and adiposity without affecting IGF-1 levels or inducing the metabolic complications typical of growth hormone therapy. This finding reinforced the notion that AOD-9604 selectively engages the lipolytic pathway of growth hormone signalling while leaving other pathways unaffected.

Clinical Evidence

The clinical evidence base differs considerably between these two peptides. Fragment 176-191 has remained primarily a preclinical research tool, with most data derived from in vitro adipocyte studies and animal models. The fragment was instrumental in establishing the concept that the C-terminal region of hGH carries lipolytic activity, but it was not itself advanced into human clinical trials as a therapeutic candidate.

AOD-9604, conversely, progressed through multiple phases of clinical development as an anti-obesity agent. Phase I and Phase II clinical trials were conducted to evaluate its safety and preliminary efficacy in overweight and obese subjects. However, these trials ultimately did not demonstrate sufficient efficacy to support continued development as an obesity treatment. As reviewed by Wilding (2004), AOD-9604 showed a favourable safety profile but the magnitude of weight loss observed in clinical studies was modest and did not meet the threshold for regulatory advancement.

More recently, AOD-9604 has been investigated for potential applications in osteoarthritis. A study by Kwon and Park (2015) examined the effects of intra-articular injection of AOD-9604, with and without hyaluronic acid, in a rabbit osteoarthritis model. The findings suggested that AOD-9604 may have chondroprotective properties, potentially representing a new avenue of investigation for this peptide beyond its original metabolic indications.

The detection and metabolism of AOD-9604 have also been subjects of analytical research, driven largely by anti-doping considerations. Cox et al. (2015) developed methods for detecting AOD-9604 and characterising its in vitro metabolic profile, while multiple research groups have established mass spectrometric approaches for identifying AOD-9604 in biological specimens.

Efficacy Comparison

Direct comparisons of efficacy between fragment 176-191 vs AOD-9604 are limited by the fact that fragment 176-191 has been studied primarily in preclinical settings, while AOD-9604 advanced to human trials. In preclinical models, both peptides demonstrate lipolytic activity, though the structural modifications in AOD-9604 were designed to enhance its metabolic stability and potentially improve its therapeutic window.

In animal models, AOD-9604 demonstrated the ability to reduce body weight gain and fat mass in obese mice over chronic treatment periods without affecting lean mass, food intake, or serum IGF-1 levels. These preclinical findings suggested a selective effect on fat metabolism that distinguished AOD-9604 from full-length growth hormone. Fragment 176-191 showed similar lipolytic effects in vitro, stimulating fat breakdown in adipocyte preparations, but direct in vivo comparisons between the two peptides are sparse in the published literature.

The clinical trial data for AOD-9604 revealed modest anti-obesity effects that fell short of the magnitude required for regulatory approval. Reviews of the obesity drug development landscape during this period noted that AOD-9604, while demonstrating a good safety profile, did not produce weight loss results comparable to other pharmacological interventions under development. This outcome led to the discontinuation of AOD-9604’s development as an obesity therapeutic, although it did not invalidate the underlying mechanistic rationale for targeting the C-terminal region of hGH.

Safety and Tolerability

Both fragment 176-191 and AOD-9604 have been associated with favourable safety profiles in the studies conducted to date, which is consistent with their design as fragments that lack the growth-promoting and diabetogenic activities of full-length growth hormone.

AOD-9604, having progressed to clinical trials, has a more substantial human safety database. Clinical studies reported that AOD-9604 was generally well tolerated, with no significant adverse effects on glucose homeostasis, insulin sensitivity, or IGF-1 levels. Importantly, research confirmed that AOD-9604 does not interfere with the WADA hGH isoform immunoassay, as demonstrated by Orlovius et al. (2013), indicating that its biological activity is distinct from that of intact growth hormone.

Fragment 176-191’s safety profile is characterised primarily through preclinical data, where it has not shown the hyperglycaemic or insulin-resistant effects associated with the full-length hormone or certain other hGH fragments. Studies by Hettiarachchi et al. (1997) comparing different hGH fragments found that the metabolic effects vary depending on the specific region of the molecule, with C-terminal fragments like 176-191 generally showing less potent effects on glucose metabolism than other regions.

Neither peptide has received regulatory approval for any therapeutic indication, and their long-term safety profiles in humans remain incompletely characterised. The anti-doping community has flagged both peptides as substances of concern, and analytical methods for their detection in biological specimens continue to be developed and refined.

Pharmacokinetics

The pharmacokinetic profiles of both peptides reflect their nature as short peptide fragments, characterised by relatively rapid absorption and clearance. As small peptides, both fragment 176-191 and AOD-9604 are susceptible to enzymatic degradation by peptidases present in plasma and tissues, which influences their bioavailability and duration of action.

AOD-9604’s structural modification—the C-terminal tyrosine addition—was designed in part to improve its metabolic stability relative to the unmodified fragment. Cox et al. (2015) characterised the in vitro metabolism of AOD-9604, identifying key degradation products and metabolic pathways. This work demonstrated that while AOD-9604 is subject to peptidase-mediated degradation, its modified structure may confer somewhat greater stability than the unmodified fragment 176-191.

Both peptides have been investigated primarily via subcutaneous or intraperitoneal routes of administration in research settings. Oral bioavailability is expected to be extremely low for both compounds due to gastrointestinal degradation, which is a common limitation of peptide-based therapeutics. The half-lives of both peptides are relatively short, consistent with their small molecular size and susceptibility to proteolytic cleavage.

More recently, analytical chemistry research has focused on developing sensitive detection methods for both peptides, driven by anti-doping requirements. Thomas et al. (2016) developed streamlined liquid chromatography and ion mobility mass spectrometry approaches for screening peptides below 2 kDa, including AOD-9604, directly from urine samples, advancing the capability to detect these compounds in biological matrices.

Current Research Status

Neither AOD-9604 nor fragment 176-191 holds current regulatory approval from the FDA, EMA, or TGA for any therapeutic indication. AOD-9604’s development as an anti-obesity agent was discontinued after clinical trials failed to demonstrate sufficient efficacy. However, the peptide has not been entirely abandoned as a research subject.

The most notable recent development involves investigation of AOD-9604’s potential in osteoarthritis, where preclinical data suggests possible chondroprotective effects. This represents a significant pivot from the peptide’s original metabolic indication and, if validated, could open new avenues for research into cartilage-protective peptides derived from growth hormone fragments.

Fragment 176-191 continues to serve primarily as a research tool for understanding the structure-function relationships within the growth hormone molecule. It remains an important reference compound in studies investigating how different regions of hGH contribute to its diverse metabolic, growth-promoting, and other biological activities.

Both peptides have been classified as prohibited substances under the World Anti-Doping Agency (WADA) code, which has driven considerable investment in analytical detection methodology. Research by multiple anti-doping laboratories has established reliable methods for identifying these compounds and their metabolites in biological samples, ensuring that their use can be monitored in competitive sport contexts.

The broader field of growth hormone fragment research continues to evolve, with emerging investigations exploring applications in tissue repair, inflammation, and cancer biology. Habibullah et al. (2022) explored the use of hGH fragment 176-191 peptide in enhancing the toxicity of doxorubicin-loaded chitosan nanoparticles against breast cancer cells, suggesting yet another potential application for this family of peptides beyond their original metabolic context.

Summary

Fragment 176-191 and AOD-9604 represent two stages in the development of C-terminal hGH-derived peptides for metabolic research. Fragment 176-191, the naturally occurring C-terminal segment of human growth hormone, established the foundational understanding that this region carries lipolytic activity independent of growth-promoting effects. AOD-9604, a structurally modified derivative incorporating a C-terminal tyrosine residue, was developed to enhance stability and advanced through clinical trials as an anti-obesity candidate.

The key distinction between fragment 176-191 vs AOD-9604 lies in their development trajectories: fragment 176-191 remains a preclinical research tool, while AOD-9604 generated human clinical data but ultimately failed to achieve regulatory approval for obesity treatment. Both peptides share a favourable safety profile characterised by the absence of the growth-promoting and diabetogenic effects of full-length hGH. Current research on AOD-9604 has shifted toward potential osteoarthritis applications, while fragment 176-191 continues to inform basic research on growth hormone structure-function relationships.

References

• Ng FM, Bornstein J. (1978). Hyperglycemic action of synthetic C-terminal fragments of human growth hormone. Am J Physiol. PMID: 645904
• Hettiarachchi M, Watkinson A, Leung KC et al. (1997). Human growth hormone fragment (hGH44-91) produces insulin resistance and hyperinsulinemia but is less potent than 22 kDa hGH. Endocrine. PMID: 9225115
• Heffernan M, Summers RJ, Thorburn A et al. (2001). The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice. Endocrinology. PMID: 11713213
• Wilding J. (2004). AOD-9604 Metabolic. Curr Opin Investig Drugs. PMID: 15134286
• Orlovius AK, Thomas A, Schänzer W, Thevis M. (2013). AOD-9604 does not influence the WADA hGH isoform immunoassay. Drug Test Anal. PMID: 24124033
• Cox HD, Smeal SJ, Hughes CM, Cox JE, Eichner D. (2015). Detection and in vitro metabolism of AOD9604. Drug Test Anal. PMID: 25208511
• Kwon DR, Park GY. (2015). Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model. Ann Clin Lab Sci. PMID: 26275694
• Thomas A, Görgens C, Guddat S et al. (2016). Simplifying and expanding the screening for peptides less than 2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry. J Sep Sci. PMID: 26578461
• Habibullah MM, Mohan S, Syed NK et al. (2022). Human Growth Hormone Fragment 176-191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells. Drug Des Devel Ther. PMID: 35783198